Related Experiment Video

Updated: Nov 17, 2025

Upper-extremity Approach for Secondary Access in Transfemoral Transcatheter Aortic Valve Implantation
06:04

Upper-extremity Approach for Secondary Access in Transfemoral Transcatheter Aortic Valve Implantation

Published on: August 8, 2025

364

Aspirin Alone Versus Dual Antiplatelet Therapy after Transcatheter Aortic Valve Replacement: A Systematic Review and

Xiaoxiao Lin1,2, Shuai Wang2, Long Wang2

  • 1Zhejiang Chinese Medical University, Hangzhou, China.

Cardiovascular Drugs and Therapy
|February 11, 2021
PubMed

Insights

Aspirin alone after transcatheter aortic valve replacement (TAVR) is as safe as dual antiplatelet therapy (DAPT) regarding mortality and stroke. Aspirin alone reduces bleeding risk compared to DAPT.

Area of Science:

  • Cardiology
  • Interventional Cardiology
  • Pharmacology

Background:

  • Current guidelines recommend dual antiplatelet therapy (DAPT) with aspirin and clopidogrel for 6 months post-transcatheter aortic valve replacement (TAVR), followed by lifelong aspirin.
  • Concerns exist regarding increased bleeding events associated with DAPT compared to aspirin monotherapy after TAVR.

Purpose of the Study:

  • To systematically review and meta-analyze randomized controlled trials (RCTs) comparing DAPT with aspirin alone following TAVR.
  • To evaluate the safety and efficacy of DAPT versus aspirin monotherapy in antithrombotic treatment after TAVR.

Main Methods:

  • Systematic review and meta-analysis of RCTs identified through Embase, PubMed, and Cochrane Library searches up to October 1, 2020.
  • Included four studies with 1086 patients (541 on aspirin, 545 on DAPT).
  • Analyzed outcomes including bleeding events, all-cause mortality, stroke, and myocardial infarction (MI) at 30 days and 6-12 months follow-up.

Main Results:

  • At 30 days, no significant difference between aspirin and DAPT for bleeding, mortality, stroke, or MI.
  • At 6-12 months, DAPT showed a statistically significant increase in bleeding events compared to aspirin alone (RR=1.67, P<0.001).
  • No significant difference in mortality, stroke, or MI between groups at 6-12 months.

Conclusions:

  • Aspirin monotherapy following TAVR is associated with a decreased risk of bleeding events compared to DAPT.
  • Aspirin alone does not appear to increase the risk of mortality, stroke, or myocardial infarction post-TAVR when compared to DAPT.
Abstract

Keywords:
AspirinDual antiplatelet therapyMeta-analysisTAVR

More Related Videos

Technique and Patient Selection Criteria of Right Anterior Mini-Thoracotomy for Minimal Access Aortic Valve Replacement08:50

Technique and Patient Selection Criteria of Right Anterior Mini-Thoracotomy for Minimal Access Aortic Valve Replacement

Published on: March 26, 2018

12.0K
Improved Registration of 3D CT Angiography with X-ray Fluoroscopy for Image Fusion During Transcatheter Aortic Valve Implantation06:59

Improved Registration of 3D CT Angiography with X-ray Fluoroscopy for Image Fusion During Transcatheter Aortic Valve Implantation

Published on: June 3, 2018

10.8K

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
838
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
124
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
112
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
113
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
171
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
123